Chapter I Aromatic Steroids : a Review I

Total Page:16

File Type:pdf, Size:1020Kb

Chapter I Aromatic Steroids : a Review I CHAPTER I AROMATIC STEROIDS : A REVIEW I. INTRODUCTION Steroids are widely distributed in nature. The basic skeleton consists of 17-carbon atoms arranged in the form of perhydrocyclopentanophenanthrene. They play an important role in the vital activity of the living organisms. Testosterone is the male sex hormone, estrone, estradiol and progesterone are female sex hormones. Hydrocortisone is a hormone of adrenal cortex. The four types of aromatic steroids viz. ring-A, ring-B, ring-C and ring-D (C-nor D-homo) occur in nature (Scheme 1). Estrone (1) the first known steroid hormone isolated by Diosy et al from the urine of pregnant women is a ring-A aromatic steroid. The structural isomer (2) of estrone isolated by 2 Heard e_t al_ from the nonphenolic fraction of equine pregnancy urine is a ring-B aromatic steroid. Viridin (3) an antifungal metabolite of Glyocladium virens is the first naturally occurring ring-C aromatic steroid which was reported as early as in 1945. Later the complete structure and stereochemistry of the compound 4 was established as represented in structure (3). Moffat and co-workers have isolated another ring-C aromatic steroid, namely viridiol (4) from the culture filters of Trichoderma viride. Veratrol (5) an alkaloid of veratrum album represents modified ring-D (C-nor D-homo) aromatic system. These aromatic steroids have been synthesized from known steroids by chemical transformations or through total synthesis. In the present review both the approaches are briefly discussed McO SCHEME 1 in the order, ring-A followed by ring-B, ring-C and ring-D aromatic steroids. II. SYNTHESIS OF A-RING AROMATIC STEROIDS J. TRANSFORMATION OF KNOWN STEROIDS Estrogens (ring-A aromatic steroids) have received most attention from the synthetic angle. Besides their total synthesis primary interest was directed towards the conversion of naturally occurring steroids into estrogens by selective aromatization of ring-A dienones. The acid catalyzed isomerization of the ring-A dienones, customarily referred to as the "dienone phenol rearrangement" has been used to convert known steroids to -^aromatic steroids. Two different substituted aromatic steroids are formed in the above rearrangement. The mechanisms are shown in Scheme 2. The position of the various functional groups in the steroid nucleus, as well as the conditions for the reaction, determine the nature of the phenols viz. whether the phenol is of the "para'' type (path A) or of the "meta" type (path B) . Any functional group which can stabilize the incipient positive charge on the secondary carbon atom (C-l) in preference to that on the tertiary carbon atom (C-5) will favour "meta" type rearrangement. Groups which fail to exert any influence both steric and electronic, will direct rearrangement leading to the formation of phenols of the "para1, type, via the inherently more stable tertiary carbonium ion. The dienone-phenol re­ arrangement has been extensively studied from these two aspects, Path A HO HO^^i^^ <Xr X Path B H^ HO SCHEME 2 Ac2O.H2S04 a r.t. 3-5 hr (92#/.) OAc Ac20' H2SOA r.t. 3hr (90*/.) Ac20,05-8hr^ ^SO* orTsOH AcO (72V.) H17 Ac?0,TsOHr 100S7hr SCHEME 3 and a comprehensive review of the available methods has appeared i 7 _ g in -j I Some typical examples of "para" and "meta" ' type rearrangements are shown in Scheme 3. In example (c) the complete conjugation of double bonds in the intermediate cation stabilizes the positive charge at C-l. The partial destabilizing effect on the generated positive charge by the dipole of the carbonyl group affords the driving force in example (d). Another method of preparing ring-A aromatic steroids from known steroids is by dehydration of the ring-A dienols. This transformation is known as the "dienol-benzene rearrange­ ment" . The rearrangement proceeds through a path which is entirely analogous to that of the dienone-phenol rearrangement, The only difference is the loss of water during the incipient stages. The accepted mechanism which is mediated through a spiran intermediate is given below. rO, r^S, -H® 2. TOTAL SYNTHESIS The isolation of estrone in 1929 paved the way for many ingenious total syntheses, each in its own way reflecting, to some extent, the state of the art of the synthesis at that time. The various approaches to the total synthesis of estrone are not only methods of its preparation but are also major 12 contributions to the synthesis of 19-norsteroids . There are eight well appreciated routes to the synthesis of estrone. Some of the typical syntheses from each route are described in the following paragraphs. (i) AB —» ABC —>• ABCD The first sjlynthesis of natural estrone by Anner and Miescher is shown in Scheme 4. The starting material viz. Robinson's ketone was synthesized from the diacid (6). Hydrogenation and esterfication of this acid gave the diester (7) Dickmcnn cyclization followed by angular methylation afforded the keto ester (8). The major product was found to possess the "natural" configuration and was designated keto ester (8A) . The Reformatsky reaction of (8A) followed by dehydration led to a mixture of isomers (9) and (10) which were separated by crystallization. A mixture of isomers (11A) and (11B) was obtained by the hydrogenation of (2J , which was 'separated by crystallization. The diester (11A) after selective hydrolysis was submitted to Arndt^Eistert reaction . Subsequent alkaline hydrolysis and cyclization gave estrone methyl ether (13). Demethylation with pyridine hydrochloride led to dl-estrone(14). COOMe S^\^COOM c MeO MtO 8 COOMe COOMe COOMe MeO MeO MeO' 8A 10 COOMe COOMe COOMe COOMe i (9) MeO MeO 11A II B .COOMe COOMc (i) CH2N2(ii) NaOH (in) S0C12 dv) CH2N2 (11)A (v)Ag20 MeOH MeO 12 13 R =Me OH H R =H (11*) MeO' MeO 15 16 SCHEME 4 In this synthesis a carbon atom is first added to the primary side chain of dimethyl marrianolate methyl ether (ItQ) and subsequently removed after cyclization. Sheehan and 16 co-workers improved the synthesis by carrying out an acyloin condensation on the diester (12$. The resulting 16-oxo derivative (15) on sodium borohydride reduction gave a mixture of epimeric alcohols (16). Dehydration of this mixture by heating with pyridine hydrochloride at 200-220 resulted in the formation of estrone (14) . m (ii) AC —» ABC —» ABCD In this approach the starting materials are biphenyl derivatives which on elaboration result in the A and C rings. Johnson's 17 ' 18 so-called second synthesis of estrone is the major contribution in this approach. The Friedel-Crafts acylation of anisole with glutaric anhydride and subsequent esterification gave the keto ester (17). Stobbe condensation with diethyl succinate, hydrogenation of the reaction product and esterification led to the formation of the triester (18) (Scheme 5). Dickmann cyclization of triester (18) with sodium hydride followed by methylation of the resulting sodio- derivative of the $-keto ester gave, the keto ester (19) of the required stereochemistry. Reformatsky reaction resulted in (20) which was ring closed by intramolecular Friedel-Crafts reaction. Acid catalyzed hydrogenation removed the 6-keto group and the double bond was saturated. The resulting dl- marrianolic acid methyl ester (21) on acyloin condensation afforded the 16-oxo derivative (15). A mixture of cis and MeO COOH MeO COOR 17 18 XOOR COOR CHCOOR MeO MeO COOR COOR 19 20 XOOR XOOR ppTH2,COOR MeO 21 15 16 SCHEME 5 trans-glycols (16)was obtained by sodium borohydride reduction of (15), which on fusion with pyridine hydrochloride (200 ) was dehydrated to estrone methyl ether (13). (Hi) AB —» ABCD The interest in the synthesis of estrone lies in the utilization of easily available starting materials such as 6-methoxy tetralone (22). Johnson and Walker 19 employed diene condensation of l-vinyl-6-methoxy-3,4-dihydronaphthalene(24) and p-benzoquinone as shown in Scheme 6. The adduct contains a double bond flanked by two carbonyl groups and which is easily reduced by zinc and acetic acid to give (25). In (25) the less hindered carbonyl group was selectively ketalized to (26). Wolff-Kishner reduction of the other carbonyl group also led to the inversion at C-14 to form the more stable C/D trans ring junction which on deketalization resulted in (27). The alkylation of benzylidene ketone 20 (28) with methyl iodide and potassium t-butoxide gave a mixture of products in which the desired trans product (29) predominated. The diacid (30) was obtained by the oxidation of (29) with alkaline hydrogen peroxide. Reduction of the conjugated 9A10-double bond with sodium in liquid ammonia resulted in the formation of the dl-homomarrionolic acid methyl ether (31), which was converted into estrone methyl ether (13). The three approaches discussed so far in this review have only historical importance since they have not been further developed. CH2 = CHMgBr 5102 McO MeO McO 22 23 24 0 MeO OMe MeOH.AcOH i)N2H^-K0H ii)AcOH Y 0 i) Additio0 n MeO ii)Zn/AcOH 26 CH.Ph Mel-tBuOK MeO COOH H ~~ Na,NH3 COOH COOH PbC03 (13) 300f McO 31 SCHEME 6 (iv) AB —*- ABD —>• ABCD By far the most important synthesis of estrone methyl 21 ether (13) is by Torgov and Aanchenko which is shown in Scheme 7. 6-Methoxy-l-vinyl~l-tetralol (23) was prepared from 6-methoxy-l~tetralone (22) and vinyl magnesium bromide. Condensation of 2-methyl-l,3-cyclopentadione with vinyl alcohol (23) gave the ABD intermediate (32) , which was ring closed by acid catalysis to the methyl ether of 3-hydroxy- 1,3,5(10),8,14-estrapentaen-17-one (33). Catalytic hydro- genation afforded the tetraene(34), which was subjected to further reduction with potassium in liquid ammonia.
Recommended publications
  • IJCB 42B(1) 166-172.Pdf
    Indian Journal of Chemistry Vol. 42B, January 2003, pp. 166-172 Synthesis and biological activity of 16-arylidene derivatives of estrone and estrone methyl ether Maninder Minu* & Dharam Paul lindal University In 5titutc of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India and G Leclercq & M Borras institut Jules Bordet, Association Hospitaliere de Bruxelles. Centre des Tumeurs de I'ULB, Rue Heger-Bordet 1- 1000, Belgiulll Received 24 April 200 I .. accepted (revised) 20 March 2002 The synthesis of 16-arylidene derivatives 3, 4, S, 6, 7. 8. 9, 10, 11, 12, 13, 14 and IS is described. These compounds have been tested at NCI, Bethesda, for their antineoplastic acti vity against the cell panel consisting of 60-ce!l lines and th e compounds 3, 4, S, 6 and 7 have also been tested for their ill vitro estrogenic / antiestrogenic activity; induction of ERE­ dependent luciferase inductio n was measured (MvLN celis). The formation of active steroids by aromatase has It was conceived that selective inhibitors of aroma­ been considered to play an important role in the de­ tase might be useful as a pharmacological tool to de­ velopment of human breast carcinoma t, at least one­ vice successful treatment approach for the hormonal third of all breast cancers establishing that. the estro­ dependent breast cancer. Our efforts were focused on gen-dependent carcinoma regresses following estro­ designing estrogen and estrogen methyl ether deriva­ 2 gen deprivation . In the postmenopausal women, the tives that might inhibit or possess antiestrogenic activ­ production of estrogen takes place in peripheral tissue ity. From these efforts, several 16-arylidine deriva­ 3 from inactive precursors by the action of aromatase .
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • EURL GUIDANCE on SUBSTANCES INCLUDED in the SUBSTANCE CATEGORIES LISTED in ANNEX I of SANTE 2017/11987
    DRAFT 24 September 2019 (EURLs ANSES, BVL and WFSR) EURL GUIDANCE ON SUBSTANCES INCLUDED IN THE SUBSTANCE CATEGORIES LISTED IN ANNEX I of SANTE 2017/11987 1. A1a Stilbenes (EURL WFSR Wageningen) Cfr. Substances listed for Group A1 in the MMPR Guidance 2. A1b Antithyroid agents (EURL WFSR Wageningen) Cfr. Substances listed for Group A2 in the MMPR Guidance 3. A1c Steroids (EURL WFSR Wageningen) Cfr. Substances listed for Group A3 in the MMPR Guidance 17b-Testosterone (4-Androsten-17b-ol-3-one) 17a-Testosterone (4-Androsten-17a-ol-3-one) 17a-Boldenone 17b-Boldenone Clostebol (CLTb) (4-androsten-4-chloro-17ß-ol-3-one) CLAD (4-chloro-4-androst-3,17-dione) (chloorandrosteendion) a-Estradiol (17a-Estradiol) 17b-estradiol (17ß-estradiol) Methylboldenone (1,4-Androstadien-17a-methyl-17b-ol-3-one) 17a-Methyltestosterone (4-Androsten-17a-methyl-17b-ol-3-one) 17b-Nortestosterone (b-nandrolone) 17α-Nortestosterone (4-estren-17a-ol-3-one) Ethinylestradiol (EE2) 17a-Trenbolone 17b-Trenbolone 16b-hydroxy-stanozolol Megestrol Melengestrol Chlormadinone Medroxyprogesterone Progesterone (P1) (4-Pregnene-3,20-dione (Pregnen(4)-3,20-dione)) Androsten-17ß-ol-3-one [1,(5a)-] (17b-1-testosteron) Mestranol (Ethynylestradiol 3-methyl ether) Fluoxymesterone (FMT) (4-androsten-9a-fluoro-17a-methyl-11ß,17ß-diol-3-one) DHEA (5-androsten-3b-ol-17-one) ethyl-5ß-estrane-3a,17ß-diol [17α-] (EED) Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) Mesterolone (Androviron) Dromostanolone (Drostanolone) 2a-Methyl-5a-androstan-3a-ol-17-one
    [Show full text]
  • United States Patent Of?Ce 3,409,643 Patented Nov
    i United States Patent Of?ce 3,409,643 Patented Nov. 5, 1968 l 2 ’ 3,409,643 choire when preparing esters atI C-17 of l7a-alkynyl-l7? PROCESS FOR THE PREPARATION OF 1711 hydroxy steroids and particularly ' ALKYNL -l7?-ALKANOYLOXY STEROIDS of those steroids which OF THE ANDROSTANE AND ESTRANE also possess functions or systems ,(e.g. 3-methoxy-A2'5(1°> SERIES , and 3-ethoxy-A3,5.-) which are highly reactive or sensitive Elliot L. Shapiro, Cedar Grove, N.J., assignor to Schering Corporation, Bloom?eld, N.J., a corporation of New hydroxyl group. Thus, Jersey preparation of 3-methoxy-17a-ethinyl-2,5(10)-esteradien . No Drawing. Filed Mar. 11, 1966, Ser. No. 533,435 17,8-01 l7_-aeetate (an intermediate in the preparation of 10 Claims. (Cl. 260-—397.5) therapeutically valuable l9-n0r steroids) via methods 10 \ known in the art involves reacting 3-methoxy-l7a-ethinyl 2,5 ( 10)-estradien-17B-ol withv acetic anhydride in pyridine ' _ABSTRACT OF THE DISCLOSURE at elevated temperatures or with acetyl chloride in pyri A novel process for the preparation of 17a-alkynyl dine. Both the aforementioned reaction mediums cause l7?-alkanoyloxy steroids of the androstane and estrane ' involving destruction of the existing series comprises subjecting a 17~keto steroid of the andro A-ring sys em such as conversion of the 3-methoxy stane and estrane series to the ' ' Azimol- sys‘em to a 3-keto-l9-nor-A4- system or to an acetylide and adding in situ to the 17a-alkynyl-l7B-hy aromatic A-ring system (i.e.
    [Show full text]
  • Labeling and Synthesis of Estrogens and Their Metabolites
    Labeling and Synthesis of Estrogens and Their Metabolites Paula Kiuru University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry P.O. Box 55, 00014 University of Helsinki, Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Science of the University of Helsinki, for public criticism in Auditorium A110 of the Department of Chemistry, A. I. Virtasen Aukio 1, Helsinki, on June 18th, 2005 at 12 o'clock noon Helsinki 2005 ISBN 952-91-8812-9 (paperback) ISBN 952-10-2507-7 (PDF) Helsinki 2005 Valopaino Oy. 1 ABSTRACT 3 ACKNOWLEDGMENTS 4 LIST OF ORIGINAL PUBLICATIONS 5 LIST OF ABBREVIATIONS 6 1. INTRODUCTION 7 1.1 Nomenclature of estrogens 8 1.2 Estrogen biosynthesis 10 1.3 Estrogen metabolism and cancer 10 1.3.1 Estrogen metabolism 11 1.3.2 Ratio of 2-hydroxylation and 16α-hydroxylation 12 1.3.3 4-Hydroxyestrogens and cancer 12 1.3.4 2-Methoxyestradiol 13 1.4 Structural and quantitative analysis of estrogens 13 1.4.1 Structural elucidation 13 1.4.2 Analytical techniques 15 1.4.2.1 GC/MS 16 1.4.2.2 LC/MS 17 1.4.2.3 Immunoassays 18 1.4.3 Deuterium labeled internal standards for GC/MS and LC/MS 19 1.4.4 Isotopic purity 20 1.5 Labeling of estrogens with isotopes of hydrogen 20 1.5.1 Deuterium-labeling 21 1.5.1.1 Mineral acid catalysts 21 1.5.1.2 CF3COOD as deuterating reagent 22 1.5.1.3 Base-catalyzed deuterations 24 1.5.1.4 Transition metal-catalyzed deuterations 25 1.5.1.5 Deuteration without catalyst 27 1.5.1.6 Halogen-deuterium exchange 27 1.5.1.7 Multistep labelings 28 1.5.1.8 Summary of deuterations 30 1.5.2 Enhancement of deuteration 30 1.5.2.1 Microwave irradiation 30 1.5.2.2 Ultrasound 31 1.5.3 Tritium labeling 32 1.6 Deuteration estrogen fatty acid esters 34 1.7 Synthesis of 2-methoxyestradiol 35 1.7.1 Halogenation 35 1.7.2 Nitration of estrogens 37 1.7.3 Formylation 38 1.7.4 Fries rearrangement 39 1.7.5 Other syntheses of 2-methoxyestradiol 39 1.7.6 Synthesis of 4-methoxyestrone 40 1.8 Synthesis of 2- and 4-hydroxyestrogens 41 2.
    [Show full text]
  • Biomarker Development to Assess Bone Health
    Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author. Biomarker development to assess bone health A thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Nutritional Science at Massey University, Palmerston North, New Zealand. Diana Leticia Cabrera Amaro 2019 Abstract Postmenopausal women experience an accelerated bone loss with increased fracture risk caused by oestrogen deficiency. Biomarkers of bone turnover assess the changes of bone metabolism in postmenopausal women; however, prediction of bone loss with these common biomarkers cannot be achieved because bone biomarkers might not reflect the bone microenvironment status. Thus, there is a need for discovering new bone biomarkers that can efficiently predict bone loss in postmenopausal women. Previous studies suggest that the ovariectomised sheep in combination with injected glucocorticoids may be a reliable model to evaluate the biological response to oestrogen withdrawal as well as the bone remodelling process. The purpose of this research programme was to test the following hypotheses: 1) ovariectomising sheep in combination with monthly injections of glucocorticoids would result in decreased bone mineral density (BMD) and increased plasma bone remodelling marker concentration over a shorter period of time; 2) the plasma metabolome and lipidome of ovariectomised sheep would be different, and the biochemical changes in plasma and bone remodelling would be associated with bone loss; 3) and finally, there would also be a difference in the plasma metabolome and lipidome of Singaporean–Chinese postmenopausal women according to their bone mineral density status.
    [Show full text]
  • Biochem Press
    Internet Electronic Journal of Molecular Design 2003, 2, 435–453 ISSN 1538–6414 BioChem Press http://www.biochempress.com Internet Electronic Journal of Molecular Design July 2003, Volume 2, Number 7, Pages 435–453 Editor: Ovidiu Ivanciuc Special issue dedicated to Professor Nenad Trinajstiü on the occasion of the 65th birthday Part 1 Guest Editors: Douglas J. Klein and Sonja Nikoliü Using Simulated 2D 13C NMR Nearest Neighbor Connectivity Spectral Data Patterns to Model a Diverse Set of Estrogens Richard D. Beger, Kathleen J. Holm, Dan A. Buzatu, and Jon G. Wilkes Division of Chemistry, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079 Received: March 21, 2003; Revised: May 2, 2003; Accepted: May 7, 2003; Published: July 31, 2003 Citation of the article: R. D. Beger, K. J. Holm, D. A. Buzatu, and J. G. Wilkes, Using Simulated 2D 13C NMR Nearest Neighbor Connectivity Spectral Data Patterns to Model a Diverse Set of Estrogens, Internet Electron. J. Mol. Des. 2003, 2, 435–453, http://www.biochempress.com. Copyright © 2003 BioChem Press R. D. Beger, K. J. Holm, D. A. Buzatu, and J. G. Wilkes Internet Electronic Journal of Molecular Design 2003, 2, 435–453 Internet Electronic Journal BioChem Press of Molecular Design http://www.biochempress.com Using Simulated 2D 13C NMR Nearest Neighbor Connectivity Spectral Data Patterns to Model a Diverse Set of Estrogens# Richard D. Beger,* Kathleen J. Holm, Dan A. Buzatu, and Jon G. Wilkes Division of Chemistry, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079 Received: March 21, 2003; Revised: May 2, 2003; Accepted: May 7, 2003; Published: July 31, 2003 Internet Electron.
    [Show full text]
  • Structure-Activity Relationships for a Large Diverse Set of Natural, Synthetic, and Environmental Estrogens
    280 Chem. Res. Toxicol. 2001, 14, 280-294 Structure-Activity Relationships for a Large Diverse Set of Natural, Synthetic, and Environmental Estrogens Hong Fang,† Weida Tong,*,† Leming M. Shi,†,‡ Robert Blair,§ Roger Perkins,† William Branham,§ Bruce S. Hass,§ Qian Xie,† Stacy L. Dial,§ Carrie L. Moland,§ and Daniel M. Sheehan§ R.O.W. Sciences, Inc., 3900 NCTR Road, MC 910, Jefferson, Arkansas 72079, and Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, Jefferson, Arkansas 72079 Received October 3, 2000 Understanding structural requirements for a chemical to exhibit estrogen receptor (ER) binding has been important in various fields. This knowledge has been directly and indirectly applied to design drugs for human estrogen replacement therapy, and to identify estrogenic endocrine disruptors. This paper reports structure-activity relationships (SARs) based on a total of 230 chemicals, including both natural and xenoestrogens. Activities were generated using a validated ER competitive binding assay, which covers a 106-fold range. This study is focused on identification of structural commonalities among diverse ER ligands. It provides an overall picture of how xenoestrogens structurally resemble endogenous 17â-estradiol (E2) and the synthetic estrogen diethylstilbestrol (DES). On the basis of SAR analysis, five distinguishing criteria were found to be essential for xenoestrogen activity, using E2 as a template: (1) H-bonding ability of the phenolic ring mimicking the 3-OH, (2) H-bond donor mimicking the17â-OH and O-O distance between 3- and 17â-OH, (3) precise steric hydrophobic centers mimicking steric 7R- and 11â-substituents, (4) hydrophobicity, and (5) a ring structure. The 3-position H-bonding ability of phenols is a significant requirement for ER binding.
    [Show full text]
  • Steroids from Carvone Promotor Prof
    Steroids from Carvone Promotor Prof. dr. Ae. de Groot, Hoogleraar in de Bio-organische Chemie, Wageningen Universiteit Co-promotoren Prof. dr. M. B. Groen, Hoogleraar aan de Vrije Universiteit Amsterdam Dr. B. J. M. Jansen, Universitair Docent bij het Laboratorium voor Organische Chemie, Wageningen Universiteit Promotiecommissie Prof. dr. J. Wicha, Institute of Organic Chemistry, Polish Academy of Sciences, Warsaw, Poland Prof. dr. H. Hiemstra, Universiteit van Amsterdam Dr. J.W. Scheeren, Radboud Universiteit Nijmegen Prof. dr. E. J. R. Sudhölter, Wageningen Universiteit Florence C. E. Sarabèr Steroids from Carvone Proefschrift ter verkrijging van de graad van doctor op gezag van de rector magnificus van Wageningen Universiteit, Prof. dr. ir. L. Speelman, in het openbaar te verdedigen op dinsdag 10 mei 2005 des namiddags te half twee in de aula Sarabèr, Florence C. E. Steroids from Carvone Thesis Wageningen University –with references and summaries in English, French and Dutch ISBN 90-8504-181-3 Contents Chapter 1 1 Introduction Chapter 2 31 Domino Mukaiyama reactions to polycyclic systems Chapter 3 63 New approach towards C,D-trans fused steroid and D-homo steroid skeletons Chapter 4 85 A new and short synthesis of C,D-cis fused steroid and D-homosteroid skeletons Chapter 5 99 A second new and short synthesis of C,D-trans fused steroid skeletons Chapter 6 127 Synthesis of a chiral ring D precursor for the generation of enantiomerically pure steroid skeletons Chapter 7 145 1-Phenylthio-3-vinyl-3-cyclohexenol, a new reagent for bis-annelation of silyl enol ethers Chapter 8 165 The use of b-cyanoketones for the synthesis of functionalized polycyclic compounds Chapter 9 177 Discussion Appendix 187 List of used abbreviations 188 Summary 189 Samenvatting 195 Résumé 201 Dankwoord 207 Curriculum vitae 209 Wanneer jij je ogen opent zullen wij, opnieuw, op weg gaan tussen de uren en hun uitvindingen en slenterend tussen de verschijningen zullen wij de tijd en zijn vervoegingen bevestigen.
    [Show full text]
  • Pharmaceutical Compoundingand Dispensing, Second
    Pharmaceutical Compounding and Dispensing Pharmaceutical Compounding and Dispensing SECOND EDITION John F Marriott BSc, PhD, MRPharmS, FHEA Professor of Clinical Pharmacy Aston University School of Pharmacy, UK Keith A Wilson BSc, PhD, FRPharmS Head of School Aston University School of Pharmacy, UK Christopher A Langley BSc, PhD, MRPharmS, MRSC, FHEA Senior Lecturer in Pharmacy Practice Aston University School of Pharmacy, UK Dawn Belcher BPharm, MRPharmS, FHEA Teaching Fellow, Pharmacy Practice Aston University School of Pharmacy, UK Published by the Pharmaceutical Press 1 Lambeth High Street, London SE1 7JN, UK 1559 St Paul Avenue, Gurnee, IL 60031, USA Ó Pharmaceutical Press 2010 is a trade mark of Pharmaceutical Press Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society of Great Britain First edition published 2006 Second edition published 2010 Typeset by Thomson Digital, Noida, India Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 912 5 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of John F Marriott, Keith A Wilson, Christopher A Langley and Dawn Belcher to be identified as the author of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • G.P. Ellis (3).Pdf
    Progress in Medicinal Chemistry 16 This Page Intentionally Left Blank Progress in Medicinal Chemistry 16 Edited by G.P. ELLIS, D.SC., PH.D.,F.R.I.C. Department of Chemistry, University of Wales Institute of Science and Technology, King Edward VII Avenue, Card& CFl 3NU and G.B. WEST, B.PHARM., D.SC., PH.D., F.I.BIOL. Department of Paramedical Sciences, North East London Polytechnic, Romford Road, London El5 4LZ 1979 NORTH-HOLLAND PUBLISHING COMPANY AMSTERDAM.NEW YORK.OXFORD 0Elsevier/North-Holland Biomedical Press - 1979 AN rights reserved. No part of this publication may be reproduced, stored in a retrieval system. or transmitted in any form or by any means, electronic. mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. ISBN for the series: 0 7204 7400 0 ISBN for this volume: 0 7204 0667 6 PUBLISHERS : Elsevier North-Holland Biomedical Press 335 Jan van Galenstraat, P.O. Box 21 1 Amsterdam, The Netherlands SOLE DISTRIBUTORS FOR THE U.S.A. AND CANADA: Elsevier/North-Holland Inc. 52 Vanderbilt Avenue New York, N.Y. 10017, U.S.A. LIBRARY OF CONGRESS CATALOGING IN PUBLICATION DATA Main entry under title: Progress in medicinal chemistry. London, Butterworths, 1961-1973 (Vols. 1-9). Amsterdam, North-Holland Publishing Co., 1974- (Vols. 10- ). Editors: 1961- G.P. Ellis and G.B. West. Includes bibliography. 1. Pharmacology-Collected works. 2. Chemistry, Medical and Pharmaceutical. I. Ellis, Gwynn Pennant, ed. 11. West, Geoffrey Buckle, 1961- ed. 111. Title: Medicinal chemistry. RS402.P78 615'.19 62-27 12 Photosetting by Thornson Press (India) Limited, New Delhi Printed in The Netherlands Preface We have pleasure in presenting five reviews in this volume.
    [Show full text]